IN2014CN00510A - - Google Patents

Info

Publication number
IN2014CN00510A
IN2014CN00510A IN510CHN2014A IN2014CN00510A IN 2014CN00510 A IN2014CN00510 A IN 2014CN00510A IN 510CHN2014 A IN510CHN2014 A IN 510CHN2014A IN 2014CN00510 A IN2014CN00510 A IN 2014CN00510A
Authority
IN
India
Prior art keywords
peptides
pcb
relates
owing
phycocyanobilin
Prior art date
Application number
Other languages
English (en)
Inventor
Rol Giselle Penton
Arzuaga Alexey Llopiz
Prida Javier Marín
Arias Eduardo Pentón
Jiménez Efraín Rodríguez
Lasa Alexis Musacchio
Pérez Vladimir Armando Besada
Andreu Gilberto Lázaro Pardo
López Luis Javier González
Fuentes Nancy Pavón
Nieto Gerardo Enrique Guillén
Saura Pedro Antonio López
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of IN2014CN00510A publication Critical patent/IN2014CN00510A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IN510CHN2014 2011-07-01 2012-06-29 IN2014CN00510A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
PCT/CU2012/000003 WO2013004203A1 (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas

Publications (1)

Publication Number Publication Date
IN2014CN00510A true IN2014CN00510A (ko) 2015-04-03

Family

ID=46614264

Family Applications (1)

Application Number Title Priority Date Filing Date
IN510CHN2014 IN2014CN00510A (ko) 2011-07-01 2012-06-29

Country Status (18)

Country Link
US (2) US9518085B2 (ko)
EP (1) EP2733149B9 (ko)
JP (1) JP6023803B2 (ko)
KR (1) KR101987978B1 (ko)
CN (1) CN103649106B (ko)
AR (1) AR087034A1 (ko)
AU (1) AU2012280776B2 (ko)
BR (1) BR112013033970B1 (ko)
CA (1) CA2838496C (ko)
CU (1) CU23963B1 (ko)
DK (1) DK2733149T3 (ko)
ES (1) ES2601887T3 (ko)
IN (1) IN2014CN00510A (ko)
MX (1) MX345534B (ko)
RU (1) RU2569302C2 (ko)
SI (1) SI2733149T1 (ko)
WO (1) WO2013004203A1 (ko)
ZA (1) ZA201309554B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183061B2 (en) * 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии
CN108752445B (zh) * 2018-06-20 2021-04-30 广东药科大学 一种螺旋藻蛋白的制备工艺及其神经保护用途
KR102152407B1 (ko) * 2019-02-26 2020-09-07 (주)나우코스 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물
KR20210091664A (ko) 2020-01-14 2021-07-22 경북대학교 산학협력단 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
US7025965B1 (en) * 2003-02-12 2006-04-11 Pharma Chemie, Inc. Method of use and dosage composition of bluegreen algae extract for inflammation in animals
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
CU23581A1 (es) * 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
ATE519491T1 (de) * 2006-06-27 2011-08-15 Nutratec S R L Zubereitung von aphanizomenon flos aquae, extrakte und gereinigte komponenten zur behandlung von neurologischen, neurodegenerativen und stimmungsstörungen
CN101677992A (zh) * 2006-11-13 2010-03-24 M·F·麦卡蒂 抑制nadph氧化酶活性的组合物

Also Published As

Publication number Publication date
EP2733149B1 (en) 2016-09-28
RU2014103246A (ru) 2015-08-10
WO2013004203A1 (es) 2013-01-10
RU2569302C2 (ru) 2015-11-20
AU2012280776B2 (en) 2016-07-14
MX345534B (es) 2017-02-03
ES2601887T3 (es) 2017-02-16
KR101987978B1 (ko) 2019-06-11
BR112013033970B1 (pt) 2022-10-18
SI2733149T1 (sl) 2017-01-31
EP2733149B9 (en) 2019-05-15
MX2013015206A (es) 2014-02-20
US20140356319A1 (en) 2014-12-04
ZA201309554B (en) 2014-08-27
JP2014520764A (ja) 2014-08-25
US20170119733A1 (en) 2017-05-04
AU2012280776A1 (en) 2014-01-23
AR087034A1 (es) 2014-02-05
EP2733149A1 (en) 2014-05-21
CN103649106B (zh) 2016-01-20
DK2733149T3 (en) 2016-11-28
US9518085B2 (en) 2016-12-13
CU23963B1 (es) 2013-12-11
CA2838496A1 (en) 2013-01-10
KR20140078601A (ko) 2014-06-25
BR112013033970A2 (pt) 2017-02-14
CA2838496C (en) 2020-01-07
CN103649106A (zh) 2014-03-19
JP6023803B2 (ja) 2016-11-09
CU20110146A7 (es) 2013-02-26

Similar Documents

Publication Publication Date Title
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP3386484A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING THERAPEUTIC AGENTS
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
HK1247957A1 (zh) T細胞輸送治療分子的組合物和方法
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2014DN10386A (ko)
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
TN2015000278A1 (en) Autotaxin inhibitors
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
IN2014CN00510A (ko)
EP3024472A4 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
HK1232242A1 (zh) 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
WO2014039074A3 (en) Therapeutic compositions and related methods
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
EP3265108A4 (en) PEPTIDES AND COMPOSITIONS AS WELL AS USES THEREOF IN THE TREATMENT OF DISEASES
EP2957569A4 (en) PEPTIDE (ARG0) N-ANGIOTENSIN- (1-7) AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES